UCB And Analysts Believe Bimekizumab Will Be Super-Blockbuster

In US, 7% of psoriasis patients are starting or switching drugs every month

 
• By Kevin Grogan
Two leading hard currencies - US Dollar versus Euro
Bimekizumab expected to be a big earner on both sides of the Atlantic • Source: Archive

More from New Products

More from Scrip